KUALA LUMPUR, Jan 13 (Bernama) -- Adagio Therapeutics Inc, a clinical-stage biopharmaceutical company has summarised recent findings reported in three separate publications that show ADG20, its lead monoclonal antibody (mAb), has neutralisation activity against the Omicron (B.1.1.529) variant of SARS-CoV-2, and outlined initiatives to address current and future SARS-CoV-2 variants of concern.
According to a statement, Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for both the prevention and treatment of COVID-19.
“SARS-CoV-2 is a quickly evolving virus, and at Adagio, we are committed to adapting just as quickly. It is abundantly clear that no single product will fully address the evolving nature of the COVID-19 pandemic, and that multiple preventative and therapeutic solutions are needed,” said co-founder and chief executive officer of Adagio, Tillman Gerngross, Ph.D.
“Based on both in-house data and third-party findings, we are confident that ADG20 can be an important tool in the fight against this virus.”
Adagio is engaging with the U.S. Food and Drug Administration (FDA) regarding potential protocol updates to its global Phase 2/3 clinical trials, including an increased dose of ADG20 for the potential prevention and treatment of COVID-19 resulting from the Omicron variant.
Recently published in vitro studies examined the neutralisation potencies of large panels of mAbs against the Omicron variant in both authentic and pseudovirus assays.
Findings across all three studies show that among mAbs in late-stage clinical development or with Emergency Use Authorization (EUA), ADG20 is one of only a few mAbs that demonstrated neutralising activity against Omicron.
Adagio is continuing evaluation of ADG20 in its EVADE and STAMP clinical trials. Adagio is engaging with the FDA on dosing strategy, including an increased dose of ADG20 and other protocol updates in light of the spread of the Omicron variant.
In addition to its clinical trial updates, Adagio is pursuing multiple strategies to address both Omicron and potential future variants that may emerge.
More details at www.adagiotx.com.
-- BERNAMA
No comments:
Post a Comment